Back to Investors
Investment Case
A diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology Manufacturers, Uniphar represents a strong combination of scale, growth and profitability.
In 2021, the Group generated revenue of €1.9 billion, gross profit of €274.5 million and EBITDA of €86.5 million. With a workforce of more than 2,900, the Group is active in Ireland, UK, Benelux, Nordics, Germany, Switzerland and USA.
Full Year 2021 Results
FY 2021 Key Stats
€86.5m
EBITDA
8.5%
Organic GP Growth YoY
17.6%
ROCE 2021
16.2c
Adjusted EPS
Group Highlights
€274.5m
2021 GP
Employees
Partnering with 7 of the top 10 pharma companies
and 7 of the top 10 medical device companies
